1. Home
  2. GANX vs HMR Comparison

GANX vs HMR Comparison

Compare GANX & HMR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • GANX
  • HMR
  • Stock Information
  • Founded
  • GANX 2017
  • HMR 1984
  • Country
  • GANX United States
  • HMR Greece
  • Employees
  • GANX N/A
  • HMR N/A
  • Industry
  • GANX Biotechnology: Pharmaceutical Preparations
  • HMR Marine Transportation
  • Sector
  • GANX Health Care
  • HMR Consumer Discretionary
  • Exchange
  • GANX Nasdaq
  • HMR Nasdaq
  • Market Cap
  • GANX 69.0M
  • HMR 67.5M
  • IPO Year
  • GANX 2021
  • HMR N/A
  • Fundamental
  • Price
  • GANX $1.64
  • HMR $1.34
  • Analyst Decision
  • GANX Strong Buy
  • HMR Strong Buy
  • Analyst Count
  • GANX 5
  • HMR 2
  • Target Price
  • GANX $8.20
  • HMR $6.00
  • AVG Volume (30 Days)
  • GANX 614.4K
  • HMR 121.8K
  • Earning Date
  • GANX 11-13-2025
  • HMR 11-11-2025
  • Dividend Yield
  • GANX N/A
  • HMR N/A
  • EPS Growth
  • GANX N/A
  • HMR N/A
  • EPS
  • GANX N/A
  • HMR N/A
  • Revenue
  • GANX N/A
  • HMR $27,657,887.00
  • Revenue This Year
  • GANX N/A
  • HMR $36.04
  • Revenue Next Year
  • GANX N/A
  • HMR $35.83
  • P/E Ratio
  • GANX N/A
  • HMR N/A
  • Revenue Growth
  • GANX N/A
  • HMR N/A
  • 52 Week Low
  • GANX $1.36
  • HMR $1.09
  • 52 Week High
  • GANX $3.19
  • HMR $10.04
  • Technical
  • Relative Strength Index (RSI)
  • GANX 43.33
  • HMR N/A
  • Support Level
  • GANX $1.55
  • HMR N/A
  • Resistance Level
  • GANX $1.78
  • HMR N/A
  • Average True Range (ATR)
  • GANX 0.13
  • HMR 0.00
  • MACD
  • GANX -0.03
  • HMR 0.00
  • Stochastic Oscillator
  • GANX 18.00
  • HMR 0.00

About GANX Gain Therapeutics Inc.

Gain Therapeutics Inc is a biotechnology company developing novel small molecule therapeutics to treat diseases across several therapeutic areas, including, lysosomal storage disorders, central nervous system disorders, metabolic disorders, and oncology. The company's clinical-stage product candidate, GT-02287, is being developed for the treatment of GBA1 Parkinson's disease. The company uses its computational target and drug discovery platform, Magellan, to discover novel allosteric binding sites on proteins implicated in disease and to identify proprietary small molecules that bind these sites to modulate protein function and treat the underlying cause of the disease. Geographically, the company operates in Switzerland, Spain, the United States, and Australia.

About HMR Heidmar Maritime Holdings Corp. Common Stock

Heidmar Maritime Holdings Corp is an asset-light tanker pool, and commercial and technical management company. The company is a fast-growing tanker pool company engaged in the commercial management and chartering of crude oil and refined petroleum product tankers. The company has also recently expanded its business to offer pool management of dry bulk vessels and technical management. The company generates maximum revenue from Singapore.

Share on Social Networks: